MA54741A - Composés thiényl-aniline destinés au traitement d'affections de la peau - Google Patents

Composés thiényl-aniline destinés au traitement d'affections de la peau

Info

Publication number
MA54741A
MA54741A MA054741A MA54741A MA54741A MA 54741 A MA54741 A MA 54741A MA 054741 A MA054741 A MA 054741A MA 54741 A MA54741 A MA 54741A MA 54741 A MA54741 A MA 54741A
Authority
MA
Morocco
Prior art keywords
thienyl
treatment
skin conditions
aniline compounds
aniline
Prior art date
Application number
MA054741A
Other languages
English (en)
Inventor
Matthew Duncton
John Kincaid
Original Assignee
Nflection Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nflection Therapeutics Inc filed Critical Nflection Therapeutics Inc
Publication of MA54741A publication Critical patent/MA54741A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA054741A 2018-11-20 2019-11-20 Composés thiényl-aniline destinés au traitement d'affections de la peau MA54741A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862769832P 2018-11-20 2018-11-20

Publications (1)

Publication Number Publication Date
MA54741A true MA54741A (fr) 2021-11-24

Family

ID=70773567

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054741A MA54741A (fr) 2018-11-20 2019-11-20 Composés thiényl-aniline destinés au traitement d'affections de la peau

Country Status (8)

Country Link
US (2) US12466818B2 (fr)
EP (1) EP3911313A4 (fr)
JP (1) JP7546297B2 (fr)
CN (2) CN113498340A (fr)
AU (1) AU2019384645B2 (fr)
CA (1) CA3120352A1 (fr)
MA (1) MA54741A (fr)
WO (1) WO2020106305A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020106305A1 (fr) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Composés thiényl-aniline destinés au traitement d'affections de la peau
EP3883552B1 (fr) 2018-11-20 2025-04-09 NFlection Therapeutics, Inc. Composés cyanoaryl-aniline pour le traitement d'affections de la peau
CN113660931B (zh) * 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤癌的芳基苯胺和杂芳基苯胺化合物
CN113473986B (zh) 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤疾病萘啶酮苯胺化合物
US11010862B1 (en) * 2019-11-14 2021-05-18 Advanced Micro Devices, Inc. Reduced bandwidth tessellation factors
KR20240125577A (ko) 2021-11-23 2024-08-19 엔플렉션 테라퓨틱스, 인코포레이티드 피롤로피리딘-아닐린 화합물의 제형

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271164A (en) 1979-04-16 1981-06-02 Warner-Lambert Company 6-Substituted-arylpyrido[2,3-d]pyrimidin-7-amines and derivatives
GB9420168D0 (en) 1994-10-06 1994-11-23 Boots Co Plc Therapeutic agents
ES2229515T3 (es) 1997-07-01 2005-04-16 Warner-Lambert Company Llc Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek.
ATE344791T1 (de) 1997-07-01 2006-11-15 Warner Lambert Co 2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren
JP2910748B2 (ja) 1997-11-12 1999-06-23 日本電気株式会社 異質同軸部材の端面の球状加工装置及びその方法
JP2002534515A (ja) 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー 1−複素環置換されたジアリールアミン
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
AU2003225161A1 (en) 2002-04-24 2003-11-10 Koo, Han-Mo Enhancement of human epidermal melanogenesis
RU2324695C2 (ru) 2002-08-06 2008-05-20 Ф.Хоффманн-Ля Рош Аг 6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Mek의 헤테로시클릭 억제제 및 그의 사용 방법
JP2008503446A (ja) 2004-05-06 2008-02-07 プレキシコン,インコーポレーテッド Pde4b阻害剤及びその使用
KR100883289B1 (ko) 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2h-피리도[2,3-d]피리미딘 유도체 및 관련 화합물
US7674907B2 (en) 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
ES2444866T3 (es) 2004-10-20 2014-02-27 Merck Serono Sa Derivados de 3-arilamino piridina
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
WO2007123939A2 (fr) 2006-04-19 2007-11-01 Laboratoires Serono S.A. Nouveaux arylamino n-hétéraryles en tant qu'inhibiteurs de mek
GB0616214D0 (en) 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
CA2658725A1 (fr) 2006-08-16 2008-02-21 Exelixis, Inc. Procedes d'utilisation de modulateurs pi3k etmek
CA2660546A1 (fr) 2006-08-21 2008-02-28 Genentech, Inc. Composes aza-benzofuranyle et leurs procedes d'utilisation
WO2008024724A1 (fr) 2006-08-21 2008-02-28 Genentech, Inc. Composés aza-benzothiophényle et leurs procédés d'utilisation
CA2666398C (fr) 2006-10-17 2015-08-18 Ed Kisak Gel de diclofenac
EP2113500A1 (fr) 2006-10-31 2009-11-04 Takeda Pharmaceutical Company Limited Inhibitêur du kinàse MAPK/ERK
CA2672327A1 (fr) 2006-11-30 2008-06-05 Genentech, Inc. Composes azaindolyliques et procedes d'utilisation de ceux-ci
JP5592253B2 (ja) 2007-05-11 2014-09-17 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性疾患およびマイトジェン細胞外キナーゼ活性関連性疾患を治療するための置換フェニルアミノ−ベンゼン誘導体
US20080312307A1 (en) * 2007-05-25 2008-12-18 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
CA2708176A1 (fr) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines et procedes d'utilisation
GB0801080D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0801081D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
WO2009093008A1 (fr) 2008-01-21 2009-07-30 Ucb Pharma S.A. Dérivés de thiénopyridine utilisés comme inhibiteurs de mek
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
CN102458402B (zh) 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
DE102010012594A1 (de) 2010-03-23 2011-09-29 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an einem oder mehreren Thiazolderivaten
US9422262B2 (en) 2010-09-24 2016-08-23 The Broad Institute, Inc. Compounds and methods for treating diseases mediated by protease activated receptors
CN103189062B (zh) 2010-11-05 2016-03-23 霍夫曼-拉罗奇有限公司 活性药物化合物用于治疗中枢神经系统病症的用途
WO2012099968A1 (fr) 2011-01-19 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions et procédés de traitement de maladies associées à un cancer de la peau
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
EP2757092A4 (fr) 2011-06-17 2015-09-23 Sinochem Corp Composés de cyanoaniline substitués, leur préparation et leur utilisation
US9357781B2 (en) 2013-05-03 2016-06-07 Inscent, Inc. Honeybee repellents and uses thereof
US10835513B2 (en) 2013-06-28 2020-11-17 The Regents Of The University Of California Methods and treatments for the learning and memory deficits associated with Noonan syndrome
US9572828B2 (en) 2013-07-18 2017-02-21 The Board Of Regents Of The University Of Texas System Treatment for melanoma
CN105384754B (zh) 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
EP3383912A4 (fr) 2015-11-30 2019-11-06 Ignyta, Inc. Formulations topiques
EP3301094A1 (fr) 2016-09-30 2018-04-04 Mutabilis Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
JP7212956B2 (ja) 2017-05-19 2023-01-26 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用のピロロピリジン-アニリン化合物
ES2913213T3 (es) 2017-05-19 2022-06-01 Nflection Therapeutics Inc Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos
WO2019139970A1 (fr) 2018-01-09 2019-07-18 Duke University Administration topique d'agents inhibiteurs de mek pour le traitement de troubles cutanés
WO2020101878A2 (fr) 2018-10-29 2020-05-22 The Johns Hopkins University Traitement de rasopathie
WO2020106304A1 (fr) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Formulations topiques
CN113473986B (zh) 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤疾病萘啶酮苯胺化合物
EP3883552B1 (fr) 2018-11-20 2025-04-09 NFlection Therapeutics, Inc. Composés cyanoaryl-aniline pour le traitement d'affections de la peau
WO2020106305A1 (fr) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Composés thiényl-aniline destinés au traitement d'affections de la peau
CN113645964B (zh) 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于胎记治疗的芳基苯胺和杂芳基苯胺化合物
CN113660931B (zh) 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤癌的芳基苯胺和杂芳基苯胺化合物
JP2023547040A (ja) 2020-09-24 2023-11-09 エヌフレクション セラピューティクス インコーポレイテッド ピロロピリジン-アニリン化合物による、認知機能不全の処置方法
CN117157065A (zh) 2021-01-21 2023-12-01 恩福莱克逊治疗有限公司 吡咯并吡啶-苯胺化合物的晶型
AU2022210443A1 (en) 2021-01-21 2023-09-07 Nflection Therapeutics, Inc. Processes for preparing pyrrolopyridine-aniline compounds

Also Published As

Publication number Publication date
CN113498340A (zh) 2021-10-12
JP2022510586A (ja) 2022-01-27
US12466818B2 (en) 2025-11-11
CN117551073A (zh) 2024-02-13
US20260167631A1 (en) 2026-06-18
EP3911313A4 (fr) 2022-10-12
JP7546297B2 (ja) 2024-09-06
US20220204486A1 (en) 2022-06-30
CA3120352A1 (fr) 2020-05-28
EP3911313A1 (fr) 2021-11-24
AU2019384645B2 (en) 2025-08-21
WO2020106305A1 (fr) 2020-05-28
AU2019384645A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
MA49141A (fr) Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau
EP3911313A4 (fr) Composés thiényl-aniline destinés au traitement d'affections de la peau
EP3883567A4 (fr) Composés naphthyridinone-aniline destinés au traitement d'affections de la peau
ECSP21093541A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
MA54229A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
MA52575A (fr) Pansement pour le traitement de la peau endommagée
EP3883552A4 (fr) Composés cyanoaryl-aniline pour le traitement d'affections de la peau
EP3448389A4 (fr) Composés de quinazoline et d'indole destinés au traitement de troubles médicaux
IL271046A (en) Compounds for treating huntington's disease
IL286340A (en) Topical formulations for treatment of peripheral neuropathies
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
EP3784260A4 (fr) Compositions pour le traitement d'affections cutanées
PL3405215T3 (pl) Sposoby leczenia choroby danona i innych zaburzeń autofagii
MA55143A (fr) Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau
EP3950686A4 (fr) Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer
EP3852745A4 (fr) Composés destinés au traitement de certaines leucémies
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
EP3790563A4 (fr) Compositions permettant le traitement d'affections cutanées
EP3664812A4 (fr) Compositions topiques pour la peau destinées au traitement de l'érythème ou de l'inflammation cutanée
EP3672587A4 (fr) Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques
EP3959213C0 (fr) Inhibiteurs de jak à base de pyrimidine pour le traitement de maladies de la peau
EP3773632A4 (fr) Méthodes de traitement de glioblastomes exprimant l'egfrviii
EP3593803A4 (fr) Composés destinés au traitement de maladies causées par l'accumulation d'oxalate
MA51738A (fr) Composés pour le traitement de la douleur
EP3927428A4 (fr) Méthodes de traitement d'affections respiratoires